Measurement-based care (MBC) means systematically measuring a patient's symptoms before or during visits and using the results to inform behavioral health treatment (Lewis et al., 2019). In practice, the patient completes a standardized questionnaire such as the PHQ-9 or GAD-7 before visits. The clinician reviews the result with the patient and uses it, with the rest of the assessment, to decide whether the treatment plan should change.
The scores describe reported symptoms at each time point. They do not confirm a diagnosis or establish why a change occurred.
What measurement-based care involves
Lewis et al. (2019) separate MBC into four core components:
- A routinely administered measure of symptoms, outcomes or process, ideally completed before each clinical encounter.
- Practitioner review of the results.
- Patient review of the same results, shared by the clinician.
- Collaborative reevaluation of the treatment plan by clinician and patient, informed by the data.
Collecting scores without the other three components does not meet that definition. A Joint Commission review of survey findings describes an organization that gave the PHQ-9 and GAD-7 only at intake and discharge. It found the results were not used to inform treatment goals during care.
The evidence
Trial results depend on how and when feedback reaches the clinician. Fortney et al. (2017) reviewed 51 articles. They reported that virtually all randomized trials with frequent and timely feedback of patient-reported symptoms during medication management and psychotherapy encounters significantly improved outcomes. One-time screening, infrequent assessment, and feedback delivered outside the clinical encounter were ineffective.
One example is a 24-week randomized trial of 120 outpatients with moderate to severe major depression. In the MBC arm, rating-scale scores guided guideline-based medication decisions. More patients in that arm reached response (86.9% vs 62.7%) and remission (73.8% vs 28.8%) on blinded HAM-D ratings. The MBC arm also had more treatment adjustments and higher antidepressant doses, so the effect reflects measurement combined with acting on it.
The evidence is not uniform. A 2016 Cochrane review pooled 12 trials with 3,696 adults with common mental health disorders. Those trials, in mental health and psychological therapy services, fed back scores from the OQ-45 or ORS outcome questionnaires. The review found no evidence of a difference in symptom outcomes. It graded that evidence as low quality because of high risk of bias, and called for better trials, particularly in primary care.
Uptake has been low. Lewis et al. (2019) report that typically less than 20% of behavioral health practitioners integrate MBC into their practice.
Choosing measures
Joint Commission guidance for behavioral health organizations lists what to look for in an MBC tool. It should have well-established reliability and validity, documented sensitivity to change, and suitability as a routine outcome measure.
The PHQ-9 for depression and the GAD-7 for anxiety each ask about the past two weeks. The PCL-5 has 20 items about PTSD symptoms over the past month. Match the measure to the condition being treated, and keep the same measure across visits so results stay comparable.
How often to measure
No single interval is established. Lewis et al. describe administration at every or most treatment sessions, but list the timing needed to optimize outcomes as an open research question. Fortney et al. found infrequent assessment ineffective.
Match the interval to the recall period of the measure. The PHQ-9 and GAD-7 each cover the past two weeks. If sessions are weekly and the questionnaire is given at each one, consecutive answers overlap by a week. Read those scores as overlapping windows, not independent snapshots. A practice can choose weekly measurement, every other session, or measurement at each medication visit. Whichever it chooses, apply it consistently and record the dates.
What MBC looks like in a session
Before seeing the patient, review the current score, the baseline, the trend over recent visits, and any item-level safety responses.
Early in the session, reference the data: "Your PHQ-9 score today is 12, similar to your last visit. You've been in the moderate range for about a month. How does that match how you've been feeling?"
Use scores to guide questions. A lower total may prompt a discussion about what changed. A flat or higher total may prompt review of symptoms, function, adherence, adverse effects, and context. The score alone does not tell you to continue, augment, switch, refer, or change monitoring.
In a study of 434 older adults in the IMPACT trial, a five-point PHQ-9 difference was the estimated minimum clinically important change. Treat a change of that size as a reason to review, not as a universal response rule. Tracking PHQ-9 scores over time covers comparing results.
Document the measure and score, the comparison with previous scores, relevant item responses, the patient's account, and your interpretation. Example: "PHQ-9 = 8, down from 14 at baseline 8 weeks ago. Patient reports improved sleep and work attendance. Reviewed the full assessment before setting the plan."
Item 9 and safety
PHQ-9 item 9 asks about thoughts of death or self-harm. Any answer above zero needs same-day follow-up under the practice's safety protocol, whatever the total or trend. A falling total does not cancel a new item 9 response, and one item is not a suicide risk assessment.
If you need help now. In the US, Call 988 or text 988. Call 911 if you are in immediate danger. Outside the US, contact your local emergency number or find support in your country.
Implementation
Lewis et al. (2019) describe barriers at four levels:
- Patient: concerns about confidentiality.
- Practitioner: the belief that measures are no better than clinical judgment.
- Organization: no resources for training.
- System: competing requirements.
The strategies they summarize include measurement feedback systems, local champions, learning collaboratives, leadership training, expert consultation with clinical staff, and incentives.
Start with one measure, one patient group and a small team, then expand. Train clinicians on the workflow, the limits of each score, and how to discuss results with patients. Explain the purpose to patients: "I'm going to ask you to complete a brief questionnaire before our appointments. It gives us the same symptom check-in over time and something concrete to discuss."
For organizations
Since 2018, Joint Commission standard CTS.03.01.09 has required accredited behavioral health care organizations to assess the outcomes of care. Its three elements of performance cover use of a standardized tool to track each person's progress and use of the data to inform that person's goals. They also cover aggregating the data to evaluate outcomes across the population served. The Joint Commission's review of survey findings reports that compliance has improved most on selecting an instrument. Using the data to improve each person's care can remain a challenge.
Aggregate scores can show completion rates, missing data, and changes in reported symptoms across a practice. They do not establish diagnosis, treatment effect, or quality of care by themselves. Measuring treatment effectiveness covers practice-level reporting.
